

8th General Assembly

September 25 & 26, 2023, Salamanca, Spain

Venue: Edificio Histórico de la Universidad de Salamanca, Escuelas Mayores,
Calle Libreros 19, 37008, Salamanca, Spain.

Agenda | Monday, 25 September 2023

09:30	Registration
10:00	<p>Words of welcome and general update on HARMONY's closure</p> <ul style="list-style-type: none"> • Jesús María Hernández, IBSAL HARMONY Alliance Coordinator • Luis Prieto Rodríguez, Novartis HARMONY Alliance Leader
10:15	<p>Presentations of HARMONY Results</p> <p>Chair: Martje Barbus, AbbVie HARMONY WP2 Co-lead</p> <ul style="list-style-type: none"> • AML: Amin Turki, Universitätsklinikum Essen Manuscript: Analysis of two decades of intensive therapy in AML: A study from the HARMONY Alliance • AML: Alberto Hernández Sánchez, IBSAL Manuscript: Rearrangements Involving 11q23.3/KMT2A in Adult Acute Myeloid Leukemia: Mutational Landscape and Prognostic Implications – Results of the HARMONY Alliance AML Database • ALL: Amir Enshaei, University of Newcastle Manuscript: Real-world evaluation of UK high hyperdiploidy profile using a large cohort of patients provided by HARMONY data platform • ALL: Marco di Bonaventura, Pfizer Manuscript: HARMONY Alliance ALL Post-SCT study • CLL: Paolo Ghia, ERIC European Research Initiative on CLL Manuscript: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY / Update: Exploring the occurrence of other malignancies in CLL patients using the HARMONY BigData platform • MM: Mattia D'Agostino, University of Turin Manuscript: Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project • AML: Sjoerd Hermans, Erasmus MC/HOVON Abstract for ASH2023: Outcome of intensively treated elderly AML patients reported to the HARMONY Alliance compares well to the outcome of control patients of the prospective randomized HOVON 103 study in elderly AML • AML: Alberto Hernández Sánchez, IBSAL Abstract for ASH2023: Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients – Results from the HARMONY Platform • APL: Luca Guarnera, University of Rome Tor Vergata Abstract for ASH2023: Long-term outcome of 1296 patients with newly diagnosed with Acute Promyelocytic Leukemia (APL): a HARMONY Alliance study
11:30	Break
12:00	<p>Update and roadmap for unfinished HARMONY Research Projects</p> <p>Chair: Guillermo Sanz, Health Institute La Fe HARMONY Co-Chair</p> <ul style="list-style-type: none"> • AML: Gert Ossenkoppele and Jesse Tetters, Amsterdam UMC Project: Measurable residual disease as surrogate marker for survival in AML: an individual patient-level correlation • AML: Rabea Mecklenbrauck, Hannover Medical School Projects: Identification of factors that can predict super-responders to chemotherapy in elderly patients with AML The impact of clonal hierarchy of unfavorable mutations in AML • ALL: Jordi Ribera, IJC Josep Carreras Leukaemia Research Institute Project: Prognostic significance of IKZF1 (Ikaros) alterations in adult B-cell precursor acute lymphoblastic leukemia • MDS: Valeria Santini, University of Florence / FiSIM-ETS Projects: Prognostic factors of treatment with hypomethylating agents (HMA) in higher risk MDS and advanced CMML Retrospective study of lenalidomide discontinuation in patients with myelodysplastic syndrome harboring del(5q) • MM: Marco di Bonaventura, Pfizer Project: Developing robust historical control arm cohorts and associated clinical outcomes among patients with multiple myeloma • MM: Diego Beltrán, Grheco-Xen / EMN Project: HARMONY subgroup analyses on early progression and long-term survival, implementation of artificial intelligence for prognostication and improvement of prognosis over time

Agenda | Monday, 25 September 2023 | continued

12:45	<p>Tools for data visualization and analytics</p> <p>Chairs: Gastone Castellani, University of Bologna and Lars Bullinger, Charité – Universitätsmedizin Berlin</p> <p>Data analytics in OMOP on the HARMONY Platform – Gastone Castellani, University of Bologna</p> <p>Presentation of the MM, MDS, ALL, CML, and AML analytics dashboards</p> <ul style="list-style-type: none"> • MM: Mattia D’Agostino, University of Turin • MDS: Valeria Santini, University of Florence / FiSIM-ETS • ALL: Amir Enshaei, University of Newcastle • CML: Jenny Rinke, Universitätsklinikum Jena • AML: Javier Martínez Elicegui, IBSAL
13:45	Lunch
15:00	<p>Parallel meetings per disease group</p> <p>Meeting rooms announced on 25th Sept according to reported attendance</p>
16:15	<p>HARMONY PLUS Research Project updates</p> <p>Chair: Jesús María Hernández, IBSAL HARMONY Coordinator</p> <ul style="list-style-type: none"> • Tiziano Barbui, FROM Research Foundation Clonal hematopoiesis confers a risk for thrombosis and cancer in MPN • Jenny Rinke, Universitätsklinikum Jena Understanding the clonal hierarchy in Chronic Myeloid Leukemia to help improve patient outcomes • Torsten Dahlén, Karolinska Institutet Using Big Data to Map and Identify Optimal Treatment Pathways to Treatment-Free Remission in CML • Jan Geissler, CML Advocates Network A comparison study of "toxicity over time" and QoL among all available TKI options / Correlation of demographic, disease and therapy factors with toxicity and tolerability of the different TKIs / Prevalence of clinically relevant problems and symptoms in patients with CML • Carmelo Gurnari, University of Rome Tor Vergata Differential outcomes of patients with MDS undergoing HSCT vs non-transplant strategies • Meral Beksac, University of Ankara External Validation of the EBMT ER Score. Will R2-ISS improve the predictive value of the EBMT early relapse score which is based on ISS and performance or response status parameters?
17:00	Break
17:30	<p>Roundtable – HARMONY PLUS: towards a mixed model. Lessons learnt from federated data initiatives in Europe</p> <p>Chair: Bill Wood, ASH Research Collaborative</p> <p>Panel</p> <ul style="list-style-type: none"> • Rubén Villoria, GMV (HARMONY PLUS) • Kimmo Porkka, University of Helsinki (FinData) • Gustavo Hernández, Universidad Politécnica de Madrid (Genomed4All) • Michel van Speybroek, Janssen (EHDEN) • Andrej Segec, European Medicines Agency (DARWIN)
18:30	Welcome words by the Rector of the University of Salamanca
19:00	Guided tour around Salamanca
20:00	Networking dinner

Agenda | Tuesday, 26 September 2023

09:00	<p>Updates about the HARMONY Alliance Foundation</p> <p>General introduction of the HARMONY Alliance Foundation</p> <p>Framework for collaboration for the different groups of beneficiaries – transitioning from HARMONY Alliance Partners and Associated Members into foundation beneficiaries</p> <ul style="list-style-type: none"> • Clinicians/data providers/academia – Lars Bullinger, Charité – Universitätsmedizin Berlin • Patients – Jan Geissler, LeukaNET / HARMONY Alliance Patient Cluster • Pharma industry – Farzad Ali, Pfizer
10:00	<p>Round table – How do international societies envision collaboration in the future?</p> <p>Chair: Konstanze Döhner, Universität Ulm / EHA president elect</p> <p>Panel</p> <ul style="list-style-type: none"> • EHA – Konstanze Döhner • MMRF – Chris Williams • iCMLf – Nicola Evans • ASH RC – Bill Wood • EBMT - Anna Surreda
11:00	<p>Break</p>
11:30	<p>Work plan for the next 18 months</p> <p>Chair: Jesús María Hernández, IBSAL</p> <ul style="list-style-type: none"> • First pilot project in the HARMONY Alliance Foundation – Novel therapies in AML – Lars Bullinger, Charité – Universitätsmedizin Berlin • Project proposal in MM as HTA use-case – Katharine Cresswell, NICE • Educational activities for young hematologists and data scientists – Ellen de Waal, EHA • Legal and Administrative action points – Willem Gruyters, PwC • Data Management and Platform action points – Jesús María Hernández, IBSAL
12:20	<p>Wrap-up and closure. Take home messages</p>
12:30	<p>Lunch</p>

Contact:

- Email: communications@harmony-alliance.eu
- Phone numbers in case of emergency:
 - o Ana Hernandez: +34 652 81 25 13
 - o Santiago Moralejo del Arco: +34 616 22 23 24
 - o Ellen de Waal: +31615102978

Last updated: 21 September 2023